医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NTT DATA Services Announces Partnership with Imbio for Lung Analytic Algorithms for UCA Imaging Platform

2016年11月28日 PM10:00
このエントリーをはてなブックマークに追加


 

CHICAGO

NTT DATA Services, formerly Dell Services, today announced its partnership with Imbio, which will provide algorithms for lung analytics. The algorithms are designed to further enhance automated tools for assisting radiology in identifying and quantifying disease present in existing and new imaging studies. The algorithms from Imbio provide for fully-automated quantification and visualization of lung structure, which is key to personalized diagnosis, surgical planning and therapy response monitoring. The Unified Clinical Archive (UCA) services from NTT DATA Services include a universal imaging analytics solution that supports machine vision and neural networks to more rapidly identify the extent of disease and accelerate the identification of incidental findings for early detection of potential chronic disease.

“We are working to break down the barriers to broader use of clinically valuable quantitative imaging,” said Dave Hannes, COO of Imbio. “This partnership with NTT DATA Services will help accelerate the availability and scalability in the cloud for fully automated lung analysis tools designed to assist routine radiological image reading. Working with the UCA solution is directly aligned with our focus on fully-automated applications to improve productivity, while making richer, personalized patient analysis accessible to all physicians.”

According to Dr. Carl Fuhrman of UPMC Radiology, “The concept of ‘personalized medicine’ is at the forefront of current medical practice with medical decisions and treatment being tailored to the individual patient. In radiology, the descriptive terminology regarding chronic obstructive pulmonary disease, such as ‘mild’ or ‘moderate,’ are no longer acceptable to accurately assess disease. Imbio allows for accurate and reproducible quantitative measurements of COPD, providing more specific measurement of disease severity and progression over serial examinations, which is crucial to our mission of personalized medicine.”

The UCA platform for imaging analytics has begun the journey of building out a broad range of machine vision and artificial intelligence tools that will enable imaging diagnosticians in radiology, cardiology and oncology to profoundly increase their insights with tools that are independent of picture archive and communication system applications but are integrated into the reporting process. The result is a greater quality and value brought from enhancing the level of detailed analysis that can be quantitatively used to help understand the anatomical imaging. These results can be used in driving patient segmentation for risk and assessing the impact of care pathways to drive more personalized individual care decisions, as well as radiology’s participation in population health.

“We’re extremely pleased to expand our cloud offerings and look forward to Imbio’s insights into emerging tools that will help our clients accelerate patient care and engagement, while also participating in driving the value of medical imaging,” said Dan Allison, president, Global Healthcare and Life Sciences, NTT DATA Services.

A demonstration of the concept on this tool and other analytics is available in NTT DATA Services booth #2504 at RSNA 2016.

About NTT Data Services – Healthcare and Life Sciences

NTT DATA Services is committed to improving patient outcomes by creating efficiencies across the healthcare ecosystem. A recognized leader in the healthcare space, the company delivers targeted segment solutions including patient engagement, predictive analytics, healthcare cloud hosting, integration and interoperability, clinical and claims application implementation, revenue cycle management and policy administration, in addition to core managed infrastructure, application and business process services. Its clients include more than 1,800 hospitals, 2,200 long-term care facilities, 225 acute care facilities, 43,000 clinicians, 1,000 physician practices and 50 insurance providers in support of 65 million policy holders.

About Imbio

Imbio is transforming medical image analysis by making breakthrough Radiology diagnostics accessible and affordable for all physicians. Imbio offers quantitative biomarker analyses that are fully automated to preserve physicians’ time while providing data and visualization to help make better personalized patient care decisions. With flexible Cloud and On-Premise SaaS solutions, Imbio makes advanced image analysis accessible to all healthcare providers directly and through strategic partners. Imbio’s commercially available Lung Density Analysis™ and Lung Texture Analysis™ are part of the company’s pulmonary portfolio supporting the diagnosis and care of chronic lung conditions. For more information, please visit www.imbio.com.

About NTT DATA

NTT DATA partners with clients to navigate the modern complexities of business and technology, delivering the insights, solutions and outcomes that matter most. We deliver tangible business results by combining deep industry expertise with applied innovations in digital, cloud and automation across a comprehensive portfolio of consulting, applications, infrastructure and business process services. NTT DATA is a top 10 global business and IT services provider with 100,000+ professionals in more than 50 countries, and is part of NTT Group, a partner to 85 percent of the Fortune 100.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161128005198/en/

CONTACT

Media
NTT DATA
Louis Adams, 214.505.3034
Louis.adams@nttdata.com
or
Imbio
David
Hannes, 262.422.4599
davidhannes@imbio.com

同じカテゴリーの記事 

  • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
  • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
  • Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China